Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Zcash (ZEC) OI Down 7.8% as NU7 Upgrade Goes Live

Zcash (ZEC) OI Down 7.8% as NU7 Upgrade Goes Live

UTodayUToday2026/11/07 07:51

Zcash open interest has declined 7.8%, according to the data from analytical platform Coinglass.

Open interest (OI) refers to the value of futures contracts that are still open. In other words, the rise in OI means more active positions.

When a price and OI decline simultaneously, it usually suggests deleveraging. The traders might be closing positions or their positions might be liquidated. 

ZEC is trading near $1,286, down 1.5% over the past 24 hours. The price’s pullback comes amid a broader market correction, with BTC down 5.75% in 24 hours.

NU7 upgrade goes live

Zcash gained 7.69% on November 4, rising on high expectations surrounding NU7. The upgrade introduces several changes to the network's transaction processing and reward structure.

As the upgrade went live on November 5, the target block interval went from 75 seconds to 25 seconds. According to the project’s statement, the change makes private payments confirm three times faster.

In addition to that, NU7 introduces a new transaction fee allocation model. 60% of the fees will go directly to a reserve for future network reserves, while the miners receive the remaining 40%.

Other changes include increased capacity for the Orchard shielded pool and new limits for wallet protection from spam.

So far, the market response has been mixed amid Friday’s correction. However, the ZEC chart is currently showing signs of an uptrend.

The price is testing support around $1,250, a level that could influence its next move. A sustained recovery above the $1,260-1,275 corridor would stabilize the further rebound.

On the other hand, a break below $1,230 would mean a failed recovery and a prolonged downtrend. 

News Image 0
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12